Last reviewed · How we verify
DWP708
DWP708 is a small molecule that targets the SGLT2 receptor.
DWP708 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DWP708 |
|---|---|
| Also known as | EGF cream |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
DWP708 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWP708 CI brief — competitive landscape report
- DWP708 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI